Ardelyx investors face November 16 class action deadline
Alpha Vantage · The National Law Review · · AI-summarised by FinFlash
Faruqi & Faruqi, LLP is reminding Ardelyx (NASDAQ: ARDX) investors of a November 16, 2026 deadline to seek lead plaintiff status in a securities class action. The suit alleges Ardelyx made misleading statements about the commercial performance and growth prospects of its drugs XPHOZAH and IBSRELA, failing to disclose increasing payer-related access and reimbursement barriers. Investors who bought Ardelyx securities between January 13, 2025 and August 6, 2026 and suffered losses may be eligible to participate.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.